Health Economics and Outcomes Research Excellence - Application Award Chair

Dan Greenberg, PhDDan_Greenberg

Associate Professor and Chairman, Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Award Background

The ISPOR Health Economics and Outcomes Research Excellence - Application Award was established in 1997 to recognize outstanding practical application of health economics and outcomes research in healthcare decision making.

Criteria:

The award is given to a distinguished example of applied health outcomes research that has or is expected to have a high impact on health policy or healthcare decision making. Preference is given to papers with creative application of health outcomes research, encompassing topics such as health policy, evaluation and adoption of health technologies, and other issues that further the goals and objectives of the Society. The award is selected by the ISPOR Excellence Awards Committee from nominated papers that have appeared in print or epublication in peer-review journals during the preceding calendar year (epublibation must be listed in Medline) and other communication venues (eg, books, reports). Self-nominations are encouraged and accepted for consideration.

A candidate may only be nominated for 1 major ISPOR award in a year.


 

Selection Process:

A call-for-nominations is placed in November-December Value & Outcomes Spotlight for articles published during the past twelve months to be considered for the ISPOR Health Economics and Outcomes Research Excellence - Application Award. In addition, each Excellence Award Committee member selects relevant publications in respected peer-reviewed journals during the preceding 12 months to be considered by the Awards Committee in the selection process. The Excellence Award Committee meets via teleconference in February to discuss each of the nominated publications. They select the best demonstration of scientific excellence for that time period. The nominee is then forwarded to the Board of Directors for final approval. The corresponding author on the publication is given the award.


 

Nature of the Award:

The award, presented at the ISPOR conference to the corresponding author of the paper, consists of a plaque, complimentary ISPOR conference registration, roundtrip air fare, hotel, meal and miscellaneous expenses for 2 days, based upon current ISPOR travel policies.

Nominations for the ISPOR Health Economics and Outcomes Research Excellence - Application Award should be accompanied by an electronic version of the nominated paper and a letter of support that illustrates the positive attributes of the paper, and be emailed to ISPOR. Only ISPOR members may submit nominations (either their own publications or others).


 

Nominate a Candidate

Nominations for the ISPOR Health Economics and Outcomes Research Excellence - Application Award should be accompanied by an electronic version of the nominated paper and a letter of support that illustrates the positive attributes of the paper, and be emailed to ISPOR. Only ISPOR members may submit nominations (either their own publications or others).

 

Recipients of the Health Economics and Outcomes Research - Application Award

Rebecca_Myerson

School of Pharmacy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, Los Angeles, CA, USA

2018 - Rebecca Myerson, MPH, PhD

For the paper, “Hospital Admissions for Myocardial Infarction and Stroke Before and After the Trans-Fatty Acid Restrictions in New York,” JAMA Cardiol 2017;2:627-634.

Rebecca Myerson, MPH, PhD, is an assistant professor at the University of Southern California and affiliate of USC’s Schaeffer Center for Health Policy and Economics. She holds a PhD in public policy with a concentration in applied econometrics from University of Chicago and an MPH from University of Washington. With the goal of informing policy to improve health, her research aims to quantify the impacts of policies on incidence and treatment of diabetes and cardiovascular disease. Her health economics research assesses whether informing patients about their health biomarkers and health insurance options closes gaps in uptake of needed care. Specific projects have analyzed trans fat restrictions, screening interventions, assistance programs for health insurance enrollment, and Medicaid eligibility expansions. Rebecca has received research funding from the Agency for Healthcare Research and Quality and a Fulbright Scholarship. Rebecca gratefully accepts this award on behalf of her coauthors, Eric Brandt, Marcelo Coca-Peraillon, and Tamar Polonsky.

Jeff_Richardson

Professor and Foundation Director, Centre for Health Economics, Monash University

2017 - Jeff Richardson, PhD

For the paper, "Measuring the Sensitivity and Construct Validity of 6 Utility Instruments in 7 Disease Areas”, Med Decis Making 2016;36:147–159.

Jeff Richardson, PhD, is a Professor and Foundation Director of the Centre for Health Economics at Monash University. He has held honorary positions at Stanford University, the Australian National University and the University of South Australia and worked as a consultant for the WHO, AusAID (the Australian foreign aid organization), and the Australian Government chairing a 2004 review of the Tasmanian health system. He was president of the Australian Health Economics Society for 7 years and a member of the tribunal, which determines pharmaceutical remuneration for 16 years. His research has included the earliest econometric modelling of the Australian health system and the first use of Cost Utility Analysis in Australia. This led to the development of the AQoL suite of utility instruments, the AQoL website and an ethical analysis of the QALY (a book co-authored with Peter Singer). Recent work has focused upon social preferences for health outcomes. He has 213 unrefereed research reports and 195 peer reviewed articles or book chapters.

Joshua_Gagne

Assistant Professor of Medicine at Harvard Medical School and a pharmacoepidemiologist in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital

2016 - Joshua J. Gagne, PharmD, ScD

For the paper, "Prospective Benefit-Risk Monitoring of New Drugs for Rapid Assessment of Net Favorability in Electronic Health Care Data", Value Health. 2015; 18:1063-1069.

Dr. Gagne is an Assistant Professor of Medicine at Brigham and Women’s Hospital and Harvard Medical School and an Assistant Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health. His research focuses on methods for generating post-approval comparative safety and effectiveness evidence for new medical products. He is Co-Lead of the Methods Core of the FDA Sentinel program. He teaches courses in pharmacoepidemiology and comparative-effectiveness research at the Harvard T.H. Chan School of Public Health, where he co-directs the Pharmacoepidemiology Program. His research is funded by AHRQ, FDA, PCORI, and the Reagan-Udall Foundation. Dr. Gagne earned his PharmD degree from the University of Rhode Island College of Pharmacy and his ScD degree in Epidemiology from the Harvard T.H. Chan School of Public Health. He serves on the editorial boards of Drug Safety and Pharmacoepidemiology and Drug Safety.

Joshua-Roth

Assistant Member, AHRQ Patient-Centered Outcomes Research K12 Scholar, Hutchinson Institute for Cancer Outcomes Research (HICOR), Fred Hutch, Seattle, WA, USA

2015 - Joshua A. Roth, PhD, MHA

For the paper, "Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study", Ann Intern Med. 2014;160:594-602.

Dr. Roth is an Assistant Member at the Hutchinson Institute for Cancer Outcomes Research at Fred Hutchinson Cancer Research Center, and an Affiliate Assistant Professor in the Pharmaceutical Outcomes Research and Policy Program at the University of Washington. Additionally, he is currently an Agency for Healthcare Research and Quality K12 scholar in patient-centered outcomes research. Dr. Roth's primary research interest is application of comparative effectiveness research methods to inform translation of lung and breast cancer therapeutics and diagnostics, including: observational study design, decision modeling, randomized controlled trial design, systematic review, and meta-analysis. His current research focuses on evaluating patient perspectives on lung cancer screening, and applying value of information analysis to identify high-value study designs for future lung cancer screening research. Dr. Roth received his PhD in pharmaceutical outcomes research from the University of Washington. He also holds a MHA degree from the department of health services at the University of Washington.

marta_soares

Researcher, Centre for Health Economics, University of York

2014 - Marta O. Soares

For the paper, “Methods to Assess Cost-Effectiveness and Value of Further Research When Data Are Sparse: Negative-Pressure Wound Therapy for Severe Pressure Ulcers”, Med Decis Making 2013 33: 415.

Marta O. Soares, is a Researcher in the Centre for Health Economics at the University of York (https://www.york.ac.uk/che/staff/research/marta-soares/). She holds an MSc in Biostatistics awarded by the University of Lisbon in 2008. Marta is currently a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee.
Marta has worked on a variety of applied projects, in clinical areas including wound care, epilepsy and sepsis. She has carried out a range of methods research in areas including expert elicitation, evidence synthesis, decision modeling and value of information analysis. Marta has also been involved in policy-focused methods development including a framework to support decision making in the face of different types of evidential uncertainty and estimation of the NICE cost-effectiveness threshold.

2013

Marisa Elena Domino, PhD

Professor, Health Policy and Management, the University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA

2012

Niteesh K. Choudhry, MD, PhD

Associate Professor, Harvard Medical School, Boston, MA, USA

2011

Craig J. Currie, PhD

Reader in Diabetes Pharmacoepidemiology, Department of Primary Care and Public Health, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff MediCentre, University Hospital of Wales, Cardiff, UK

2010

Ties Hoomans, PhD, MSc

Post Doctoral Research Fellow, Health Technology Assessment Research Program, School for Public Health and Primary Care, Maastricht University, The Netherlands

2009

Maureen Rutten van Mölken, PhD

Associate Professor Health Economics, Institute for Medical Technology Assessment, Erasmus University/Erasmus Medical Centre, Rotterdam, The Netherlands

2008

Greg Zaric, PhD

Associate Professor, Management Science group, Richard Ivey School of Business, and Associate Professor of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario

2007

John Hsu, MD, MBA, MSCE

Physician Scientist, Kaiser Division of Research, Kaiser Institute for Health Policy

2006

Josephine A. Mauskopf, PhD

Economics MHA, Health Administration
MA, Physiology/Pharmacology
Duke University

2005

Dr. Schneeweiss

2004

Emily R. Cox, PhD

2003

Jean-Michel Gaspoz, MD, MSc

Clinique de Medecine II and the Division of Cardiology, Hopitaux Universitaires, Geneva, Switzerland

2002

David W. Baker, MD, MPH

Associate Professor of Medicine and Epidemiology- Biostatistics at the Center for Health Care Research and Policy, MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio

2001

Jean M. Mitchell, PhD

2000

Michael K. Gould, MD, MSc

1999

Sean Sullivan, PhD

1998

Deborah J. Partsch, PharmD

1997

Nelda Johnson, PharmD